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Abstract
A series of simplified berberine analogs was designed, synthesized, and evaluated for anti-
inflammatory activity.  SAR studies identified N-benzyl tetrahydroisoquinoline 7d as a potent 
berberine analog.  7d suppressed LPS-induced inflammatory cytokine levels in both BV2 cells 
and primary microglia.  Taken together, our results suggest that simplified BB analogs have 
therapeutic potential as a novel class of anti-neuroinflammatory agents. 
  
1. Introduction
Multiple sclerosis (MS) is an autoimmune disorder that is characterized by the deterioration of 
the insulating myelin sheath of neurons in the central nervous system1.  The interactions of 
antigen-presenting CNS microglia, CNS infiltrating myelin-specific T cells, and other cells result 
in the release of pro-inflammatory mediators, ultimately causing brain inflammation leading to 
myelin deterioration2.  The symptoms of the disorder are related to the extent of neuronal 
damage and the location of attack, but can include numbness/weakness in the limbs, vision 
problems, tremor, slurred speech, electric-shock sensations, fatigue, and bowel and bladder 
control problems3.  
The importance of inflammation in MS is underscored by the immunomodulatory activity of the 
current MS therapies.  While there are over a dozen disease-modifying MS agents available for 
the most common type of the disease (relapsing/remitting), there is currently no cure.  
Additionally, nearly one third of patients develop severe disability.  As such, the identification of 
novel anti-neuroinflammatory agents is warranted.  
Figure 1.  Structure of berberine chloride.  
The benzylisoquinolium alkaloid berberine (BB, Figure 1), found in several plant species, has 
been shown to possess multiple interesting pharmacological properties, including anticancer, 
antibacterial, antifungal, antidiabetic, and anti-inflammatory activities4.  Excitingly, BB has been 
demonstrated to ameliorate inflammatory processes in the experimental autoimmune 
encephalomyelitis (EAE) model of neuroinflammation5, 6.  This anti-inflammatory activity has 
been attributed to modulation of numerous cellular pathways in immune cells, including AMPK, 
MAPK, Nrf2, and NF-κB7.  
While BB has promising anti-inflammatory activity, it has limited utility as a therapeutic agent.  
BB suffers from poor solubility, limited absorption, and low bioavailability8, 9.  Additionally, BB is 
reported to undergo extensive metabolism with the production of multiple metabolites, some 
of which are pharmacologically active10.  The unfavorable pharmacokinetic properties of BB 
likely are a consequence of several features of its chemical structure: the presence of a 
contiguous ring system, a permanent positive charge and metabolically-sensitive isoquinolium 
and alkoxy moieties.
The drug-like properties of BB can likely be improved via structural modification.  Numerous 
structure-activity relationships (SAR) studies have been reported for BB; however, most of 
  
these studies evaluated analogs that are alkylated and/or phenolic derivatives of BB11-13.  While 
many of these compounds have displayed interesting activities, most are sufficiently similar to 
BB to still suffer from poor physicochemical properties.  Furthermore, few of these studies 
explored anti-inflammatory activity.  Herein, we report a structure-activity relationships study 
of simplified BB analogs as anti-neuroinflammatory agents.  
2.  Chemistry
2.1 Design of initial series of molecules
To probe the structural features of BB that contribute to its anti-inflammatory activity, a series 
of structurally-diverse molecules was designed (1-7a).  The roles of the stationary positive 
charge of the isoquinolium nitrogen, along with the role of planarity on ring D, were evaluated 
by designing tetrahydroberberine 1 and benzalkonium 2. The functions of rings C and D were 
assessed by designing molecules 5-7a.  
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Scheme 1.  Synthesis of simplified berberine analogs. 
2.2 Synthesis
  
Compound 1 was prepared as previously described by reducing berberine chloride with NaBH4 
in MeOH14.  Analog 2 was synthesized by treating 1 with benzyl bromide in refluxing CH3CN11.  
Treatment of amide 3 with first POCl3 followed by NaBH4 provided secondary amine 415.  
Methylation of 4 with MeI in refluxing CH3CN gave amines 516 and 6.  N-benzyl analogs 7 were 
prepared by reductive amination of appropriate benzaldehydes with corresponding 
tetrahydroisoquinolines using NaBH(OAc)3 in dichloroethane in good yields.  Amide 10 was 
prepared by activating acid 9 with PyBOP with subsequent coupling to amine 8.  
3.  Results and discussion
3.1 Evaluation of BB analogs and structure-activity relationship analysis
Tumor necrosis factor (TNF) is one of several important pro-inflammatory cytokines produced 
by immune cells, including microglia17.  TNF has been found to be elevated at sites of active MS 
lesions and contributes to processes that damage oligodendrocytes and myelin18-20.  Given the 
importance of TNF in neuroinflammation, synthesized BB analogs were evaluated for their 
ability to suppress TNF levels induced by lipopolysaccharide (LPS) in the BV2 immortalized 
mouse microglial cell line.  BV2 cells were pretreated with test compounds at a concentration 
of 50 μM for 1 h, then stimulated with LPS for 24 h, at which time the media was collected and 
assayed for TNF levels via ELISA.  BB was evaluated at a concentration of 1 μM as higher 
concentrations did not provide additional TNF suppression (data not shown).  The results are 
expressed in Table 1 and are expressed as a percentage of LPS.  
As shown in Table 1, treatment of BV2 cells with LPS caused a ten-fold increase of TNF levels.  
Synthesized molecules demonstrated a range of activities, from significant TNF suppression to 
minimal.  Interestingly, the presence of a permanent cationic nitrogen was as a common 
feature of the most potent molecules assayed (BB and 2).  The nature of the cationic amine 
appears to be less important, as both isoquinolium (BB) and benzalkonium cations (2) were 
tolerated.  However, enhanced activity does not seem to apply to cation 6 as minimal TNF 
suppression was observed (97% of LPS).  
Entry TNF levels (% LPS)
DMSO 10 ± 2.3
LPS 100 ± 0
BB (1 uM) 25 ± 8.2
1 45.0 ± 12
2 22 ± 9.1
4 77 ± 2.4
5 77 ± 5.7
6 97 ± 7.0
7a 1-9 (R1, R2 = -CH2OCH2-), R3 = 2, 3-OMe 63 ± 8.6
Table 1.  Suppression of TNF by synthesized compounds.  BV2 cells were treated with DMSO or experimental 
compounds (50 μM) for 1 hour, followed by LPS (100 ng/mL) activation for 24 hour.  The culture media was 
collected and TNF levels evaluated by ELISA.  Data are expressed as mean ± SEM and are representative of three 
different experiments.  
  
One of our approaches to improve the physicochemical properties of BB was to eliminate its 
permanent positive charge.  We were pleased to see that activity can be retained by 
substitution of the isoquinolium core of BB for tetrahydroisoquinoline (1).  This molecule 
suppressed TNF levels to 45% of LPS, suggesting that this portion of the BB molecule is 
amendable to modification.   
Ring connectivity also appears to influence TNF suppression.  The activity of molecules with the 
D ring of BB removed appears to depend on the site of C-D ring junction.  Compound 7a, 
connected to ring D via N9, was more active (63% of LPS) than the analogs 4-6 (77, 77, and 97 % 
of LPS, respectively), all of which are connected via C18.  Indeed, the introduction of an 
asymmetric center into these compounds may also impact activity.  
While 1 and 2 were the most active of the molecules synthesized, their chemical structures still 
possessed features that were not ideal, namely positive charges and/or a contiguous ring 
system.  N-Benzyl tetrahydroisoquinoline 7a, with its modest activity and synthetic simplicity, 
seemed a good candidate for optimization.  Thus, we designed, synthesized, and evaluated a 
second series of analogs in an effort to increase TNF-suppression.  The results are shown in 
Table 2.  
Entry R1 R2 R3 TNF levels (% LPS)
DMSO 10 ± 2.3
LPS 100 ± 0
7b H H 2, 3-OMe 95 ± 9.4
7c -CH2OCH2- Ph 90 ± 13
7d -CH2OCH2- 2, 6-OMe 39 ± 10
7e -CH2OCH2- 3, 5-OMe 89 ± 5.2
7f -CH2OCH2- 4-OMe 88.± 6.8
7g -CH2OCH2- 4-CF3 102 ± 14
7h -CH2OCH2- 2, 4-OMe 103 ± 13
7i -CH2OCH2- 2-OMe 78 ± 4.0
7j -CH2OCH2- 3-OMe 78 ± 9.6
7k H H 2, 6-OMe 78 ± 11
7l -CH2OCH2- 2, 6-Me 101 ± 1.3
7m -CH2OCH2- 2, 6-Cl 107 ± 6.9
7n H OMe 2, 6-OMe 82 ± 5.0
7o OMe H 2, 6-OMe 64 ± 9
10 73 ± 11
Table 2.  Suppression of TNF by synthesized compounds.  BV2 cells were treated with DMSO or experimental 
compounds (50 μM) for 1 hour, followed by LPS (100 ng/mL) activation for 24 hour.  The culture media was 
collected and TNF levels evaluated by ELISA.  Data are expressed as mean ± SEM and are representative of three 
different experiments.  
Compound 7b lacks the methylenedioxy group of 7a.  This moiety appears to be important for 
activity as TNF suppression was greatly reduced by its removal (95% of LPS).  The substitution of 
the N-benzyl group was next explored by assaying compounds 7c-j.  Excitingly, a substitution 
  
pattern 2, 6-dimethoxy (7d) resulted in the most TNF suppression (39% of LPS, compared to 
61% for 7a). In contrast, 2, 4- and 3, 5-dimethoxy substituted analogs 7h and 7e gave minimal 
activity, as did monomethoxy congeners 7f, i and j, and trifluoromethyl analog 7g.  N-Benzyl 
analog 7c also showed minimal activity (89% of LPS). 
The introduction of a 2, 6-dimethoxy moiety into compound 7a clearly augmented its activity; 
however, it was not clear the extent to which the activity of 7d could be attributed to this 
substitution.  As such, we synthesized and assayed compounds 7k-o.  Confirming what was 
observed for 7c, removal the methylenedioxy of 7d (7k) weakened TNF suppression (79% of 
LPS).  Interestingly, this activity can be partially restored by incorporation of a 6-OMe (7o, 64% 
of LPS), but to a lesser extent than a 7-OMe (7n, 82% of LPS) group.  The electronic properties 
of the 2, 6-dimethoxy moiety of 7d appear to be crucial, as 2, 6-dimethyl (7l) or 2, 6-dichloro 
groups (7m) resulted in loss of TNF suppression (101 and 107% of LPS, respectively). 
As a cationic nitrogen was seen to give the most activity in BB and 1, it appeared likely that an 
ionizable nitrogen is needed for 7d’s activity.  This was probed by synthesizing and assaying 
amide 10.  Expectedly, this molecule was quite weaker than parent 7d (73 vs. 39% of LPS, 
respectively).  While this decrease in activity is likely due to the loss of ionizability, introduction 
of conformational restriction may also be involved.
The rationale for the improved activity of 7d over 7a is not clear.  However, examining low 
energy conformations of BB and 7d yields a possible explanation (Figure 2).  The minimized 
conformation of BB produces an essentially flat structure due to the high degree of sp2 
hybridization in the molecule.  The minimized conformation for 7d suggests that the 
tetrahydroisoquinoline and N-benzyl ring systems are in a perpendicular relationship to each 
other.  Overlaying these two structures shows the methylenedioxy, amine, and 12-methoxy 
groups of BB lining up with their counterparts in 7d.  The other methoxy group of 7d does not 
seem to overlap with a group in BB.  It is possible that this methoxy group is accessing an 
additional binding site in its target.  As the 6 position of the N-benzyl ring of 7a is unsubstituted, 
this interaction is not possible, and may contribute the weaker activity compared to 7d.   
Figure 2.  Low energy conformations of BB and 7d using Chem3D.   
3.2 Suppression of pro-inflammatory cytokines by 7d
  
As described above, the production of pro-inflammatory cytokines and mediators are important 
to the pathophysiology of MS.  We next assayed the suppression of these molecules by various 
concentrations of 7d in LPS-stimulated BV2 cells.  Treatment with LPS alone caused a large 
increase in TNF release (ten-fold compared to DMSO, Figure 3).  Interestingly, treatment with 
7d was able to dose-dependently decrease TNF protein levels was seen beginning at a 
concentration of 12 μM, and continued to decrease up to 50 μM. IL-6, another pro-
inflammatory cytokine, has been demonstrated to be upregulated in both the plasma and CNS 
of MS patients21, 22.  As seen for TNF, 7d was able to suppress LPS-mediated IL-6 induction in a 
dose-dependent manner, in BV2 cells, beginning at a concentration of at 25 μM.  
Figure 3.  Suppression of TNF, IL-6, and nitrate by 7d.  BV2 cells were treated with 7d at various concentrations for 
one hour, followed by LPS (100 ng/mL) for 24 hours.  Culture media was then collected and assayed for respective 
inflammatory products.  Data are expressed as mean ± SEM and are representative of three different experiments.  
Statistical significance determined as * p < 0.05, ** p < 0.01 and *** p < 0.001.
Nitric oxide (NO) is produced by microglia in response to inflammatory stimuli, and is known to 
contribute to oligodendrocyte injury, demyelination, and axonal degeneration23.  As NO is 
converted rapidly to nitrite under physiological conditions, levels of NO2 were assayed in LPS-
stimulated BV2 cells.  As seen in Figure 3, LPS treatment induced significant nitrite production.  
However, treatment with 7d ameliorated this increase dose-dependently.  
The interleukins IL-12, formed from p35 and p40 subunits, and IL-23, formed from p19 and p40 
subunits, are important in the development of the pro-inflammatory TH1 and TH17 helper T cell 
phenotypes, respectively24.  Both of these cell types have are associated with EAE and MS.  As 
such, the mRNA expression of these molecules, along of IL-1β, GM-CSF, TNF, and IL-6 was 
assessed in LPS-stimulated primary mouse microglia cells.  As shown in Figure 4, expression of 
these genes was increased upon LPS stimulation.  Excitingly, however, treatment with 7d (100 
μM) suppressed all but IL-12p40 and TNF, after both 2 and 4 hours of LPS exposure.  The 
suppression of inflammatory cytokines and mediators by 7d in LPS-stimulated BV2 cells and 
primary microglia suggest that this compound has anti-neuroinflammatory activity.  
  
Figure 4.  Suppression of inflammatory cytokines by 7d.  Primary microglia cells were treated with 7d (100 uM) for 
one hour, followed by stimulation with LPS (100 ng/mL) for 2 and 4 hours.  Cells were then harvested and 
subjected to RNA extraction followed by QPCR analysis of IL-1β, IL-23p19, IL-12p35, IL-12p40GM-CSF, TNF, and IL-
6.  Data are expressed as mean ± SEM and are representative of three different experiments.  Statistical 
significance determined as * p < 0.05, ** p < 0.01 and *** p < 0.001.
The current unmet medical in need in MS treatment warrants the development of additional 
therapeutic options.  The identification of novel small molecules that target additional 
inflammatory targets may improve treatment.  The anti-inflammatory activity of simplified 
analog 7d represents an advancement in the exploration of BB as an immunomodulatory agent.  
Future planned studies include the determination of mechanism of action of 69, additional 
structure-activity relationship studies to improve potency, and evaluation the in vivo EAE model 
of neuroinflammation.   
4.  Conclusion
The isoquinolium alkaloid BB is widely known for its multiple pharmacological activities.  
However, the therapeutic potential of this interesting natural product is hampered by 
  
unfavorable pharmacokinetic properties arising from aspects of its chemical structure.  The 
results of our studies have delineated the important structural features of BB that influence its 
anti-inflammatory activity.  These studies identified simplified lead compound 7d, which 
suppressed LPS-induced inflammatory mediators in both the BV2 cell line and primary 
microglia, suggesting a potential role for simplified BB analogs as anti-neuroinflammatory 
agents.     
5.  Experimental 
5.1 Chemistry
All solvents and reagents obtained from commercial sources were used without further 
purification, unless otherwise noted.  Berberine chloride was purchased from TCI (Tokyo, 
Japan).  All reactions were performed under an inert argon atmosphere, unless otherwise 
indicated.  The purity of all final molecules was judged by elemental analyses (C, H, N) and were 
found to be within ± 0.4% of theoretical values.  1H and 13C NMR analyses were performed on a 
Varian Mercury 300 spectrophotometer at 300 and 75 MHz, respectively.  Chemical shifts are 
given in ppm in reference to tetramethylsilane (TMS) as an internal standard.  Multiplicities are 
given as s (singlet), d (doublet), t (triplet), m (multiplet), and br s (broad signal).  High-resolution 
mass spectral data were obtained on a Waters Acquity TQD triple quadrupole mass 
spectrometer.  Melting points were taken on a Mel-Temp apparatus and are uncorrected.  Thin 
layer chromatography (TLC) was performed on silica gel 60 F254-coated glass plates purchased 
from EMD Millipore, and visualized with UV light and/or basic KMnO4.  Rf values correspond to 
the free base, where applicable.  Low energy conformations were generated using Chem3D.  
General reductive amination procedure.  To a solution of tetrahydroisoquinoline (1.41 mmol) 
and AcOH (2.82 mmol) in (CH2Cl)2 (5mL) at room temperature was added benzaldehyde (1.41 
mmol).  The resulting solution was stirred for 15 min, at which time NaBH(OAc)3 (2.82 mmol) 
was added.  The reaction was allowed to proceed overnight, poured into 1 M NaOH (10 mL), 
and extracted 3 times with CH2Cl2.  The pooled organic extracts were washed with H2O, dried 
over Na2SO4, filtered and concentrated.  The crude residue was then purified by flash 
  
chromatography (CH2Cl2/MeOH).  Purified N-benzylamines were next converted to their 
corresponding hydrochloride or oxalate salts.  
5-(3,4-dimethoxybenzyl)-6,6-dimethyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-6-ium 
iodide (6).   Tetrahydroisoquinoline 5 (31 mg, 0.095 mmol) and MeI (0.500 mmol) were refluxed 
in acetonitrile for 4 hours.  The reaction mixture was cooled and concentrated.  The crude solid 
was recrystallized from isopropyl alcohol to afford 6 as a white solid (56 mg, 59%).  1H NMR 
(300 MHz, DMSO-d6) δ 6.91 – 6.83 (m, 2H), 6.69 (d, J = 2.1 Hz, 1H), 6.64 (dd, J = 8.2, 2.0 Hz, 1H), 
5.97 (d, J = 0.9 Hz, 1H), 5.93 (d, J = 0.9 Hz, 1H), 5.88 (s, 1H), 4.78 (dd, J = 9.4, 4.0 Hz, 1H), 3.81 – 
3.54 (m, 8H), 3.32 (s, 4H), 3.11 - 3.08 (m, 5H), 2.89 (dd, J = 13.5, 9.4 Hz, 1H).  13C NMR (75 MHz, 
DMSO) δ 148.6, 147.8, 147.2, 145.2, 128.0, 123.6, 122.7, 122.0, 113.5, 111.7, 108.3, 107.9, 
101.2, 71.3, 55.6, 55.5, 53.9, 51.4, 50.4, 36.9, 23.3.  HRMS (ESI) m/z calcd for: C21H26NO4  M+ = 
356.1862, found: 365.1850.
6-(2,3-dimethoxybenzyl)-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline oxalate  (7a).  
Yield: 77%.  White solid (m.p. = 218 – 220 oC).  1H NMR (300 MHz, DMSO-d6) δ 7.18 – 6.97 (m, 
3H), 6.72 (d, J = 4.7 Hz, 2H), 5.96 (s, 2H), 4.10 (s, 2H), 3.93 (s, 2H), 3.83 (s, 3H), 3.77 (s, 3H), 3.13 
(t, J = 6.1 Hz, 2H), 2.87 (t, J = 6.1 Hz, 2H). 13C NMR (75 MHz, DMSO) δ 163.4, 152.4, 147.7, 146.4, 
145.7, 126.3, 125.5, 124.0, 123.5, 122.9, 113.4, 108.1, 106.4, 100.8, 60.5, 55.7, 53.5, 53.1, 49.1, 
26.2.  Rf = 0.4 (EtOAc).  HRMS (ESI) m/z calcd for: C19H21NO4 [M+H]+ = 328.1549, found: 
328.1548. 
2-(2,3-dimethoxybenzyl)-1,2,3,4-tetrahydroisoquinolineoxalate (7b).  Yield: 67%.  White solid 
(m.p. = 167 -169 oC) 1H NMR (300 MHz, DMSO-d6) δ 9.88 (s, 2H), 7.27 – 7.03 (m, 7H), 4.12 (s, 
2H), 4.05 (s, 2H), 3.83 (s, 3H), 3.78 (s, 3H), 3.17 (t, J = 6.1 Hz, 2H), 2.98 (t, J = 6.1 Hz, 2H).  13C 
NMR (75 MHz, DMSO) δ 163.4, 152.4, 147.7, 132.4, 130.9, 128.4, 126.9, 126.5, 126.4, 126.1, 
124.0, 122.9, 113.4, 60.5, 55.7, 53.7, 53.2, 49.1, 26.3.  Rf = 0.5 (EtOAc).  HRMS (ESI) m/z calcd 
for: C18H22NO2 [M+H]+ = 284.1651, found: 284.1640.
  
6-benzyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline hydrochloride (7c).  Yield: 91%.  
White solid (m.p. = 235 -238 oC) 1H NMR (300 MHz, DMSO-d6) δ 11.66 (s, 1H), 7.77 – 7.55 (m, 
2H), 7.47 (dp, J = 4.8, 1.9 Hz, 3H), 6.77 (d, J = 7.1 Hz, 2H), 5.98 (s, 2H), 4.40 (d, J = 6.3 Hz, 2H), 
4.13 (t, J = 4.4 Hz, 2H), 3.55 (s, 1H), 3.20 (d, J = 10.8 Hz, 2H), 2.92 (q, J = 13.3, 11.4 Hz, 1H).  13C 
NMR (75 MHz, DMSO) δ 146.8, 146.0, 131.3, 129.8, 129.4, 128.7, 124.8, 120.9, 108.1, 106.3, 
101.0, 57.9, 51.0, 48.1, 24.7.  Rf = 0.4 (EtOAc).  HRMS (ESI) m/z calcd for: C17H18NO2 [M+H]+ = 
268.1338, found: 268.1324.
6-(2,6-dimethoxybenzyl)-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline oxalate (7d).  
Yield: 76%.  White solid (m.p. =  218 -220 oC) 1H NMR (300 MHz, DMSO-d6) δ 7.41 (t, J = 8.4 Hz, 
1H), 6.79 – 6.71 (m, 4H), 5.98 (s, 2H), 4.17 (s, 2H), 4.07 (s, 2H), 3.82 (s, 6H), 3.28 (d, J = 6.5 Hz, 
2H), 2.92 (t, J = 6.3 Hz, 2H).  13C NMR (75 MHz, DMSO) δ 164.1, 159.2, 158.6, 133.1, 131.6, 
128.0, 121.6, 113.1, 113.0, 107.0, 104.2, 56.0, 55.2, 52.2, 49.0, 47.4, 25.5.  Rf = 0.4 (EtOAc).  
HRMS (ESI) m/z calcd for: C19H22NO4 [M+H]+ = 328.1546, found: 328.1544.
6-(3,5-dimethoxybenzyl)-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline oxalate (7e).  
Yield: 81%.  White solid (m.p. =  219 -221oC) 1H NMR (300 MHz, DMSO-d6) δ 6.74 (d, J = 4.5 Hz, 
2H), 6.67 (d, J = 2.3 Hz, 2H), 6.52 (t, J = 2.2 Hz, 1H), 5.97 (s, 2H), 4.07 (s, 2H), 3.93 (s, 2H), 3.75 (s, 
6H), 3.14 (t, J = 6.2 Hz, 2H), 2.89 (t, J = 6.1 Hz, 2H).  13C NMR (75 MHz, DMSO) δ 164.1, 161.0, 
146.9, 146.3, 126.0, 123.7, 108.6, 108.4, 107.0, 101.3, 100.8, 59.8, 55.7, 53.3, 49.4, 26.5.  Rf = 
0.3 (EtOAc).  HRMS (ESI) m/z calcd for: C19H22NO4 [M+H]+ = 328.1546, found: 328.1545.
6-(4-methoxybenzyl)-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline hydrochloride (7f).  
Yield: 94%.  White solid (m.p. =  231 -233oC) 1H NMR (300 MHz, DMSO-d6) δ 11.48 (s, 1H), 7.63 – 
7.55 (m, 2H), 7.07 – 6.95 (m, 2H), 6.77 (d, J = 5.8 Hz, 2H), 5.98 (s, 2H), 4.43 – 4.24 (m, 2H), 4.10 
(d, J = 5.4 Hz, 2H), 3.79 (s, 3H), 3.54 (d, J = 4.3 Hz, 1H), 3.23 – 3.12 (m, 2H), 2.97 – 2.82 (m, 1H). 
13C NMR (75 MHz, DMSO) δ 160.0, 146.8, 146.0, 132.8, 124.8, 121.5, 121.0, 114.1, 108.1, 106.3, 
101.0, 57.5, 55.2, 50.8, 47.9, 24.7.  Rf = 0.4 (EtOAc).  HRMS (ESI) m/z calcd for: C18H20NO3 
[M+H]+ = 298.1443, found: 298.1435.
  
6-(4-(trifluoromethyl)benzyl)-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline oxalate (7g).  
Yield: 67%.  White solid (m.p. = 219 -222 oC) 1H NMR (300 MHz, DMSO-d6) δ 7.83 – 7.64 (m, 4H), 
6.72 (s, 1H), 6.68 (s, 1H), 5.95 (s, 2H), 4.12 (s, 2H), 3.82 (s, 2H), 3.04 (t, J = 6.0 Hz, 2H), 2.85 (t, J = 
6.1 Hz, 2H).  13C NMR (75 MHz, DMSO) δ 163.0, 146.2, 145.6, 139.1, 130.6, 128.9, 128.5, 125.8, 
125.4, 125.3, 124.2, 108.1, 106.3, 100.7, 59.1, 53.4, 49.4, 26.7.  Rf = 0.4 (EtOAc).  HRMS (ESI) 
m/z calcd for: C18H17FNO2 [M+H]+ = 336.1200, found: 336.1203.
6-(2,4-dimethoxybenzyl)-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline oxalate (7h).  Yield: 70%.  
White solid (m.p. =  187 -189 oC) 1H NMR (300 MHz, DMSO-d6) δ 7.36 (d, J = 8.4 Hz, 1H), 6.75 (d, J = 
4.8 Hz, 2H), 6.64 (d, J = 2.4 Hz, 1H), 6.59 (dd, J = 8.4, 2.4 Hz, 1H), 5.98 (s, 2H), 4.10 (s, 2H), 4.00 
(s, 2H), 3.82 (s, 3H), 3.80 (s, 3H), 3.20 (t, J = 6.3 Hz, 2H), 2.90 (t, J = 6.3 Hz, 2H).  13C NMR (75 
MHz, DMSO) δ 163.1, 161.4, 159.2, 146.5, 145.9, 132.7, 125.6, 123.4, 112.8, 108.1, 106.4, 
105.4, 100.8, 98.7, 55.7, 55.4, 53.4, 52.8, 48.8, 26.1.  Rf = 0.3 (EtOAc).  HRMS (ESI) m/z calcd for: 
C19H22NO4 [M+H]+ = 328.1540, found: 328.1542.
6-(2-methoxybenzyl)-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline oxalate (7i).  Yield: 
78%.  White solid (m.p. = 208 - 210 oC1H NMR (300 MHz, DMSO-d6) δ 7.54 – 7.32 (m, 2H), 7.20 – 
7.07 (m, 1H), 7.00 (t, J = 7.3 Hz, 1H), 6.74 (d, J = 7.0 Hz, 2H), 5.97 (s, 1H), 4.12 (s, 1H), 3.97 (s, 
1H), 3.83 (s, 1H), 3.17 (s, 1H), 2.90 (d, J = 6.0 Hz, 1H).  13C NMR (75 MHz, DMSO) δ 163.9, 157.9, 
146.5, 145.8, 132.1, 130.6, 125.2, 122.8, 120.4, 111.2, 108.1, 106.4, 100.9, 55.5, 53.1, 52.5, 
48.8, 25.6.  Rf = 0.5 (EtOAc).  HRMS (ESI) m/z calcd for: C18H20NO3 [M+H]+ = 298.1443, found: 
298.1436.
6-(3-methoxybenzyl)-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline oxalate (7j).  Yield: 
83%.  White solid (m.p. = 235 -238 oC).  1H NMR (300 MHz, DMSO-d6) δ 7.33 (t, J = 7.8 Hz, 1H), 
7.09 – 6.89 (m, 3H), 6.72 (d, J = 7.9 Hz, 2H), 5.95 (s, 2H), 4.04 (d, J = 10.6 Hz, 2H), 3.91 – 3.81 (m, 
2H), 3.76 (s, 3H), 3.08 (d, J = 8.7 Hz, 2H), 2.87 (d, J = 6.5 Hz, 2H).  13C NMR (75 MHz, DMSO) δ 
162.9, 159.7, 146.5, 145.9, 135.7, 129.7, 126.1, 124.4, 122.2, 115.5, 114.2, 108.2, 106.5, 100.8, 
  
60.0, 55.3, 53.6, 49.7, 26.7.  Rf = 0.4 (EtOAc).  HRMS (ESI) m/z calcd for: C18H20NO3 [M+H]+ = 
298.1443, found: 298.1440.
2-(2,6-dimethoxybenzyl)-1,2,3,4-tetrahydroisoquinoline oxalate (7k).  Yield: 96%.  White solid 
(m.p. = 193 -195 oC).  1H NMR (300 MHz, DMSO-d6) δ 7.41 (t, J = 8.4 Hz, 1H), 7.31 – 7.11 (m, 4H), 
6.75 (d, J = 8.4 Hz, 2H), 4.19 (s, 4H), 3.82 (s, 6H), 3.39 – 3.28 (m, 2H), 3.03 (t, J = 6.4 Hz, 2H).  13C 
NMR (75 MHz, DMSO) δ 163.3, 159.2, 132.1, 131.1, 130.3, 128.3, 127.1, 126.6, 126.1, 108.1, 
104.3, 56.0, 52.9, 49.2, 47.7, 39.8, 25.6.   Rf = 0.5 (EtOAc).  HRMS (ESI) m/z calcd for : C18H22NO2 
[M+H]+ = 284.1651, found: 284.1642.
6-(2,6-dimethylbenzyl)-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline oxalate (7l).  Yield: 
63%.  White solid (m.p. = 196 -198 oC1H NMR (300 MHz, DMSO-d6) δ 7.33 – 6.93 (m, 3H), 6.68 
(s, 2H), 5.93 (s, 2H), 3.86 (s, 2H), 3.81 – 3.63 (m, 2H), 2.92 (s, 2H), 2.75 (t, J = 6.0 Hz, 2H), 2.37 (s, 
6H).  13C NMR (75 MHz, DMSO) δ 161.9, 146.1, 145.7, 138.2, 132.8, 128.3, 127.6, 126.6, 126.2, 
108.2, 106.4, 100.6, 54.7, 54.6, 49.8, 27.9, 19.9.  Rf = 0.4 (EtOAc).  HRMS (ESI) m/z calcd for: 
C19H22NO2 [M+H]+ = 296.1651, found: 296.1645.
6-(2,6-dichlorobenzyl)-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline oxalate (7m).  Yield: 
67%.  White solid (m.p. =  153 - 157 oC) 1H NMR (300 MHz, DMSO-d6) δ 7.55 – 7.46 (m, 2H), 7.38 
(dd, J = 8.9, 7.1 Hz, 1H), 6.63 (d, J = 4.2 Hz, 2H), 5.92 (s, 2H), 3.94 (s, 2H), 3.68 (s, 2H), 2.85 (t, J = 
5.9 Hz, 2H), 2.70 (t, J = 5.9 Hz, 2H).  13C NMR (75 MHz, DMSO) δ 161.3, 145.8, 145.4, 136.2, 
130.3, 128.7, 126.4, 108.1, 106.3, 100.5, 55.3, 54.9, 50.1.  Rf = 0.4 (EtOAc).  HRMS (ESI) m/z 
calcd for: C17H16NO2Cl2 [M+H]+ = 336.0559, found: 336.0558.
2-(2,6-dimethoxybenzyl)-7-methoxy-1,2,3,4-tetrahydroisoquinoline oxalate (7n).  Yield: 69%.  
White solid (m.p. = 180 -181 oC1H NMR (300 MHz, DMSO-d6) δ 7.41 (t, J = 8.4 Hz, 1H), 7.12 (d, J 
= 8.4 Hz, 1H), 6.84 (dd, J = 8.4, 2.7 Hz, 1H), 6.80 – 6.68 (m, 3H), 4.17 (d, J = 15.0 Hz, 4H), 3.82 (s, 
6H), 3.73 (s, 3H), 3.33 (s, 2H), 2.95 (t, J = 6.4 Hz, 2H).  13C NMR (75 MHz, DMSO) δ 164.1, 159.1, 
  
157.7, 131.5, 130.6, 129.5, 123.5, 114.0, 111.2, 106.7, 104.0, 55.9, 55.2, 52.4, 49.2, 47.2, 24.3.  
Rf = 0.5 (EtOAc).  HRMS (ESI) m/z calcd for: C19H24NO3 [M+H]+ = 314.1756, found: 314.1764.
2-(2,6-dimethoxybenzyl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline oxalate (7o).  Yield: 55%.  
White solid (m.p. =  186 – 188 oC) 1H NMR (300 MHz, DMSO-d6) δ 7.41 (t, J = 8.4 Hz, 1H), 7.10 
(d, J = 8.4 Hz, 1H), 6.87 – 6.57 (m, 4H), 4.19 (s, 2H), 4.13 (s, 2H), 3.82 (s, 6H), 3.74 (s, 3H), 3.44 – 
3.22 (m, 2H), 3.02 (t, J = 6.4 Hz, 2H).  13C NMR (75 MHz, DMSO) δ 164.1, 159.2, 158.6, 133.1, 
131.6, 128.0, 121.6, 113.1, 113.0, 107.0, 104.2, 56.0, 55.2, 52.2, 49.0, 47.4, 25.5.  Rf = 0.5 
(EtOAc).  HRMS (ESI) m/z calcd for: C19H24NO3 [M+H]+ = 314.1756, found: 314.1751.
(7,8-dihydro-[1,3]dioxolo[4,5-g]isoquinolin-6(5H)-yl)(2,6-dimethoxyphenyl)methanone (10).  
To a solution of 2,6-dimethoxybenzoic acid (150 mg, 0.824 mmol) in DMF (3 mL) was added 
sequentially trimethylamine (2.74 mmol) and PyBOP (514 mg, 1.00 mmol).  The solution was 
stirred at ambient temperature for 10 minutes.  Next, 5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-
g]isoquinoline (146 mg, 0.824 mmol) was added and the reaction was allowed to proceed for a 
further 3 hours, at which time the solution was poured into water (50 mL) and extracted three 
times with Et2O (50 mL).  The pooled organic extracts were washed with H2O, dried over 
Na2SO4, filtered and concentrated.  The crude residue was then purified by flash 
chromatography (EtOAc) to yield the titled compound (221 mg, 79%).  White solid (m.p. = 161 – 
164 oC). NMR analysis showed the presence of two rotamers in a ratio of 2:1, which was 
confirmed by temperature-resolved NMR experiments (see Supporting Information). 1H NMR 
Major rotamer: (300 MHz, DMSO-d6) δ 7.34 (t, J = 8.4 Hz, 1H), 6.82 (s, 1H), 6.78 – 6.64 (m, 3H), 
5.96 (s, 2H), 4.65 (s, 2H), 3.73 (s, 6H), 3.30 (dd, J = 6.3, 5.4 Hz, 2H), 2.61 (t, J = 5.8 Hz, 2H).  1H 
NMR Minor rotamer: (300 MHz, DMSO-d6) δ 7.33 (t, J = 8.4 Hz, 1H), 6.75 - 6.69 (m, 3H), 6.58 (s, 
1H), 5.93 (s, 2H), 4.17 (s, 2H), 3.75 (t, J = 5.8 Hz, 2H), 3.63 (s, 6H), 2.73 (t, J = 5.8 Hz, 2H).  13C 
NMR Combined rotamers (101 MHz, DMSO) δ 164.7, 156.7, 156.6, 146.3, 146.2, 146.1, 146.1, 
130.8, 130.7, 128.1, 127.8, 126.9, 126.5, 115.0, 114.8, 108.9, 108.8, 107.0, 106.4, 104.8, 104.7, 
101.1, 101.0, 56.2, 47.8, 43.9, 43.7, 29.3, 28.4.  HRMS (ESI) m/z calcd for: C19H19NO5 [M+H]+ = 
342.1341, found: 342.1335.  
  
5.2 Pharmacology
5.2.1  Cell culture conditions
The BV2 microglial cell line a generous gift from Dr. Yen (Fort Wayne, IN).  Cells were grown in 
DMEM:F-12 media (1:1) supplemented with 10% heat-inactivated FBS and 100 U/mL penicillin 
and 100 μg/mL streptomycin in 150 cm2 culture flasks in a humidified atmosphere of 5% CO2.  
The media was replaced every 2 days, and cells were subcultured once a confluence of 70-80% 
was reached.  All test compounds were dissolved in DMSO and diluted in media (final DMSO 
concentration of 0.1% v/v).
Primary MG were generated as previously described.25 Briefly, cerebral cortical cells from 1-2 
days old neonatal mice were plated in 75-cm2 culture flasks DMEM/F12 (1:1) supplemented with 
10% heat-inactivated FBS, containing 2mM glutamine and 1X antibiotic/antimycotic (complete 
medium).  After days 3 and 6 of plating, the medium was removed and replaced with fresh 
complete medium containing 5 ng/ml GM-CSF.  MG were then harvested at day 13 or 14 by 
shaking the flasks at 350 rpm for 30 min at 37°C.  Collected cells were subsequently plated for 
use.    
5.2.2 Cytokine quantification assay
BV2 cells were plated in 12 well plates at a density of 5 x 105 cells/mL and allowed to attach 
overnight.  Cells were then treated with either DMSO or test compounds for one hour, followed 
by LPS (E. coli O55:B5, 100 ng/mL, Sigma) treatment for 24 hours.  Media was then collected, 
centrifuged to remove floating cells, and either assayed immediately or frozen at -80 oC for 
future use.  TNF or IL-6 levels were determined using Ready Set Go! ELISA kit from 
Thermofisher. 
5.2.3  Nitrate quantification assay
  
BV2 cells were plated in 12 well plates at a density of 5 x 105 cells/mL and allowed to attach 
overnight.  Cells were then treated with either DMSO or test compounds for one hour, followed 
by LPS treatment for 24 hours.  Media was then collected, centrifuged to remove floating cells, 
and either assayed immediately or frozen at -80 oC for future use.  Media samples were assayed 
for nitrite levels using the Greis assay kit from Thermofisher.  
5.2.4  QPCR analysis
After collection primary MG were plated (5 x 105 cells/mL) and allowed to attach overnight.  
Cells were then treated with either DMSO or test compound for one hour, followed by LPS (100 
ng/mL) for 2 and 4 hours.  Following treatment, primary MG were subjected to RNA extraction, 
purification, and quantification using the Trizol reagent (Thermofisher), followed by cDNA 
synthesis using the High Capacity Reverse Transcription cDNA kit (Thermofisher). Expression of 
Il-1β, Il-12p35, Il-12p40, Il-23p19, GM-CSF, TNF, and Il-6 were detected by quantitative PCR as 
previous described.26 The primers used were Il-1β: sense 5’-CCCTGCAGCTGGAGAGTGTGGA-3’ 
and antisense 5’-TGTGCTCTGCTTGGAGGTGCTG-3’; Il-12p35: sense 5’-
CTGTGCCTTGGTAGCATCTATG -3’ and anti-sense 5’-GCAGAGTCTCGCCATTATGATTC-3’; Il-12p40: 
sense 5’-TGGTTTGCCATCGTTTTGCTG-3’ and antisense 5’-ACAGGTGAGGTTCACTGTTTCT-3’; Il-
23p19: sense 5’-TGCTG GATTGCAGAGCAGTAA-3’ and anti-sense 5’-
GCATGCAGAGATTCCGAGAGA-3’; GM-CSF: sense 5’-ATGCCTGTCACGTTGAATGAAG-3’ and anti-
sense 5’-GCGGGTCT GCACACATGTTA-3’; TNF: sense 5’-ATGGCCTCCCT-CTCATCA-GT-3’ and 
antisense 5’-CTTGGTGGTTTGCTACGACG-3’; IL-6: sense 5’-TCCTCTCTGCAAGAGACTTCCATCC-3’ 
and antisense 5’-GGGAAGG-CCGTGGTTGTCACC-3’.
6.  Statistical analysis
Results are expressed as mean ± SEM.  Comparisons among multiple groups were done by one-
way ANOVA, followed by Dunnett’s post hoc test.  Statistical significance was determined as p 
values ≤ 0.05.  GraphPad Prism 5 was used to perform all analyses.  
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